Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label satralizumab in NMOSD (Japan extension)
jRCT2031200333Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Long-term safety of satralizumab, Time to first relapse (TFR) and 8 more. Started Mar 2021; status: completed.
02
Drugs
satralizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on jRCT2031200333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200333.